Jay Flatley

Jay Flatley
Name	Jay Flatley
Birth date	1954
Birth place	Des Moines, Iowa, United States
Occupation	Business executive, entrepreneur
Known for	Leadership at Illumina
Alma mater	Iowa State University (BS, MS)

Jay Flatley

Jay Flatley is an American business executive and entrepreneur known for leading a major biotechnology company through commercialization of DNA sequencing technologies. He has been influential in corporate strategy, product development, and industry consolidation within the biotechnology and life sciences sectors. Flatley’s leadership intersected with prominent companies, academic institutions, and government initiatives involved in genomics, diagnostics, and precision medicine.

Early life and education

Flatley was born in Des Moines, Iowa, and pursued undergraduate and graduate studies at Iowa State University, where he studied industrial administration and mechanical engineering-related fields. During his time at Iowa State University, he engaged with research and campus organizations that connected to regional industry partners such as 3M, DuPont, and Ford Motor Company. He later participated in executive education and professional programs affiliated with institutions like Stanford University and Harvard Business School through professional development and industry conferences.

Career

Flatley began his career in product development and operations at companies including Honeywell, HBOC-linked enterprises, and firms that interacted with IBM and Texas Instruments. He moved into executive roles at medical device and biotechnology companies, holding leadership positions that involved interactions with organizations such as Medtronic, GE Healthcare, and Boston Scientific. Flatley joined a sequencing-focused company that merged into Illumina, where he served in senior management and subsequently as chief executive officer and chairman, overseeing relationships with partners and competitors like Applied Biosystems, Roche, Thermo Fisher Scientific, Qiagen, and Pacific Biosciences. Under his tenure, the company expanded global operations, engaging markets across United States, United Kingdom, China, Japan, and Germany and working with academic centers such as Broad Institute, Cold Spring Harbor Laboratory, Wellcome Sanger Institute, and National Institutes of Health.

Flatley navigated corporate finance, mergers and acquisitions, and public markets, interacting with entities including Goldman Sachs, Morgan Stanley, JP Morgan Chase, Nasdaq, and Securities and Exchange Commission. He engaged with regulatory and policy stakeholders like U.S. Food and Drug Administration, European Medicines Agency, and funding bodies such as National Science Foundation and Wellcome Trust. After stepping down from operational leadership, Flatley continued involvement as an investor, advisor, and director for technology and life sciences firms, connecting with venture capital and private equity firms including Sequoia Capital, Kleiner Perkins, and Accel Partners.

Contributions to genomics and technology

Flatley played a central role in transitioning next-generation sequencing from research instrumentation to widely adopted platforms used in clinical and research settings. Under his leadership, the company released platforms and workflows that affected projects like the Human Genome Project follow-on initiatives, population genomics efforts such as the 1000 Genomes Project and regional efforts in China, United Kingdom, and Iceland. The commercialization efforts enabled collaborations with translational research centers including Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Stanford Medicine, and cancer research institutions like Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.

Technological advances promoted during his tenure influenced fields tied to companies and consortia such as Illumina, Broad Institute–MIT, Genome Canada, Genomics England, and diagnostic initiatives involving Avantor and Agilent Technologies. Flatley oversaw scaling of manufacturing and supply chains with partners including Foxconn-linked assemblers, Siemens, and global distributors, while also participating in dialogues about ethics and governance with organizations like National Academy of Sciences, World Health Organization, World Economic Forum, and patient advocacy groups including Cancer Research UK and American Cancer Society.

Awards and honors

Flatley received recognition from business and industry organizations, academic institutions, and trade groups. Honors and listings have included acknowledgments from Forbes, Fortune, Wall Street Journal, Biotechnology Industry Organization (now Advanced Bioeconomy Leadership Conference-related entities), and awards from regional economic development organizations tied to San Diego and Silicon Valley. He has been invited to speak at forums such as TED, World Economic Forum meetings in Davos, and conferences hosted by American Association for the Advancement of Science and Bio.

Philanthropy and board memberships

Flatley has served on corporate and nonprofit boards, contributing to governance at institutions and companies such as Illumina (board roles), academic advisory boards at Iowa State University, and philanthropic initiatives linked to biomedical research and education. His board and advisory engagements have included participation with hospitals and research centers like Scripps Research, Rady Children's Hospital-San Diego, and foundations such as Gates Foundation-partnered projects, regional economic development organizations, and venture-backed startups focusing on diagnostics, therapeutics, and data analytics. He has supported scholarships, research funding, and community programs in partnership with local organizations in San Diego County, Des Moines, and broader U.S. and international philanthropic networks.

Category:1954 births Category:People from Des Moines, Iowa Category:American chief executives in the biotechnology industry